Influenza Viral Challenge Study of CC-42344 in Healthy Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) challenge virus. Participants will not know whether they are getting placebo or CC-42344. The amount of virus in nasal samples will be measured over time. Side effects and pharmacokinetics (the amount of CC-42344 in blood) will also be measured.
Epistemonikos ID: cbd934ccde617e41d1cf799998ed5e6744601570
First added on: May 15, 2024